Cidara Therapeutics - CDTX Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.67
  • Forecasted Upside: 576.33%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.69
▼ -0.02 (-2.82%)

This chart shows the closing price for CDTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cidara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CDTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CDTX

Analyst Price Target is $4.67
▲ +576.33% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cidara Therapeutics in the last 3 months. The average price target is $4.67, with a high forecast of $6.00 and a low forecast of $3.00. The average price target represents a 576.33% upside from the last price of $0.69.

This chart shows the closing price for CDTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 investment analysts is to buy stock in Cidara Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/22/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
11/6/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
9/22/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
9/22/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00Low
9/8/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00Low
9/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
8/7/2023HC WainwrightReiterated RatingBuy$6.00Low
8/4/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$3.00Low
8/1/2023HC WainwrightReiterated RatingBuy$6.00Low
8/1/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$5.00Low
3/23/2023HC WainwrightLower TargetBuy$6.50 ➝ $6.00Low
3/8/2023Cantor FitzgeraldReiterated RatingOverweight$5.00Low
3/1/2023HC WainwrightReiterated RatingBuy$6.50Low
1/25/2023HC WainwrightBoost TargetBuy$6.00 ➝ $6.50Low
5/12/2022HC WainwrightLower Target$7.50 ➝ $6.00High
3/16/2022AegisReiterated RatingBuyHigh
3/8/2022Needham & Company LLCReiterated RatingBuy$6.00High
12/16/2021WedbushBoost TargetOutperform$5.00 ➝ $6.00High
12/3/2021HC WainwrightInitiated CoverageBuy$6.00Medium
9/22/2021AegisLower TargetBuy$9.00 ➝ $8.00High
9/22/2021WBB SecuritiesUpgradeBuy ➝ Strong-Buy$6.25High
3/4/2021AegisInitiated CoverageBuy$9.00High
11/6/2020Maxim GroupReiterated RatingBuy$10.00High
8/26/2020CitigroupLower TargetBuy$6.00 ➝ $5.00High
8/14/2020Maxim GroupReiterated RatingBuy$10.00Medium
8/14/2020Needham & Company LLCInitiated CoverageBuy$6.00Medium
8/13/2020OppenheimerReiterated RatingBuy$6.00Low
5/21/2020Maxim GroupInitiated CoverageBuy$10.00Medium
5/14/2020Needham & Company LLCInitiated CoverageBuy$6.00Medium
3/10/2020Maxim GroupInitiated CoverageBuyLow
3/5/2020Needham & Company LLCLower TargetBuy$10.00 ➝ $6.00Medium
12/4/2019WBB SecuritiesUpgradeSpeculative Buy ➝ Buy$6.25Medium
9/4/2019BTIG ResearchReiterated RatingBuy$7.00High
9/3/2019WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $4.00High
8/12/2019Needham & Company LLCSet TargetBuy$10.00High
6/12/2019Cantor FitzgeraldLower TargetOverweight ➝ Reduce$15.00 ➝ $8.00Low
6/5/2019OppenheimerInitiated CoverageOutperform$6.00High
5/17/2019WedbushDowngradeOutperform ➝ Neutral$2.00High
4/15/2019Cantor FitzgeraldReiterated RatingBuy$15.00Medium
3/1/2019WedbushLower TargetOutperform ➝ Outperform$12.00 ➝ $7.00Low
(Data available from 2/22/2019 forward)

News Sentiment Rating

0.93 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/27/2023
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/26/2023
  • 4 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/25/2023
  • 6 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/25/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/24/2023
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/24/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/23/2024
  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/22/2024

Current Sentiment

  • 4 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Cidara Therapeutics logo
Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also advances its Cloudbreak platform to develop conjugates for the prevention and treatment of influenza and other viral infections, such as RSV, HIV, and the SARS-CoV-2 strains causing COVID-19. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.
Read More

Today's Range

Now: $0.69
Low: $0.68
High: $0.70

50 Day Range

MA: $0.73
Low: $0.64
High: $0.82

52 Week Range

Now: $0.69
Low: $0.59
High: $2.10

Volume

328,808 shs

Average Volume

509,323 shs

Market Capitalization

$62.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Cidara Therapeutics?

The following Wall Street sell-side analysts have issued stock ratings on Cidara Therapeutics in the last year: Cantor Fitzgerald, HC Wainwright, Needham & Company LLC, StockNews.com, and TheStreet.
View the latest analyst ratings for CDTX.

What is the current price target for Cidara Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Cidara Therapeutics in the last year. Their average twelve-month price target is $4.67, suggesting a possible upside of 576.3%. HC Wainwright has the highest price target set, predicting CDTX will reach $6.00 in the next twelve months. Needham & Company LLC has the lowest price target set, forecasting a price of $3.00 for Cidara Therapeutics in the next year.
View the latest price targets for CDTX.

What is the current consensus analyst rating for Cidara Therapeutics?

Cidara Therapeutics currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CDTX will outperform the market and that investors should add to their positions of Cidara Therapeutics.
View the latest ratings for CDTX.

What other companies compete with Cidara Therapeutics?

How do I contact Cidara Therapeutics' investor relations team?

Cidara Therapeutics' physical mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company's listed phone number is (858) 752-6170 and its investor relations email address is [email protected]. The official website for Cidara Therapeutics is www.cidara.com. Learn More about contacing Cidara Therapeutics investor relations.